Back to Results
First PageMeta Content
AFP-L3 / Biomarker / Hepatocellular carcinoma / Alpha-fetoprotein / Liver cancer / Medicine / Tumor markers / Hepatology


Wako Diagnostics Press Release - July 29th, 2013 Wako Diagnostics granted Medical Device Licences from Health Canada for the μTASWako® i30 Immunoanalyzer, and AFP-L3 and DCP Assays for Liver Cancer Risk Assessment
Add to Reading List

Document Date: 2014-02-04 16:53:12

Open Document

File Size: 158,27 KB

Share Result on Facebook

City

Osaka / Mountain View / /

Company

Wako Life Sciences Inc. / Wako Pure Chemical Industries Ltd. / Wako Diagnostics Wako Diagnostics / Wako Diagnostics / /

Country

Japan / United States / Canada / South Korea / /

Event

FDA Phase / /

IndustryTerm

microfluidic chips / healthcare professionals / owned subsidiary / chemicals / /

MedicalCondition

cancers / cancer / hepatocellular carcinoma / chronic liver disease / liver cancer / liver disease / /

OperatingSystem

L3 / /

Organization

FDA / /

Person

Shinji Satomura / /

Position

President / Major / /

Product

L3 / /

ProvinceOrState

California / /

Technology

alpha / Microfluidics / /

URL

www.wakodiagnostics.com / /

SocialTag